ByTrending Posts
Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission…
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster…
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound…
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or…
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at…
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play…
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are…
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
Obesity Market Poised for $200B+ US Breakthrough by…
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040 on 20-25% sustained…
AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked…
AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment and 30% OpEx…
Trending Posts
Latest Stories
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1…
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology,…
How Does Merck Architect a $70 Billion Post-Keytruda Fortress Through 2030?
Merck executes a “One Pipeline” diversification masterplan, tripling late-stage assets since 2021 to deliver 20+ potential…
How Does Sanofi Transform Immunology Dominance Into €20+ Billion Revenue Through 2030?
Sanofi masterminds a “multi-indication immunology powerhouse” strategy, surgically channeling R&D toward 12 blockbuster candidates (3 “pipeline-in-a-product” assets…
Gallery
